EBITDA has never been a sufficient measure of performance in healthcare services, and the sooner private equity firms stop treating it as the default screen, the better. The real signal lives in the operational details: accounts receivable days, payer mix, and the underlying revenue cycle mechanics that determine whether a practice can actually convert volume into cash. For firms evaluating healthcare targets, these are not back-office footnotes. They are the difference between a platform that looks healthy on paper and one that will quietly bleed value through denied claims, slow collections, and unfavorable reimbursement contracts.
What this means in practice is that screening must start earlier and dig deeper. A target with strong EBITDA but deteriorating AR days is not a fixer-upper; it is a warning sign that management has been managing to the income statement, not to the business. Payer mix matters just as much. A practice overly dependent on a single commercial payer or heavy government reimbursement carries a risk profile that no amount of revenue growth can mask. The firms that internalize this will avoid the trap of underwriting a turnaround that never materializes. Those that do not will keep paying for the same painful lesson.
The practical implication for investors is straightforward: build diligence around these operational metrics from the first pass, not as a phase-two deep dive. That means asking for the aging schedule alongside the CIM, tracking collection trends by payer, and stress-testing what happens if a major contract renegotiates at a lower rate. It is less glamorous than modeling out growth assumptions, but it is where the actual downside protection lives. In a sector where reimbursement pressure is structural and labor costs keep rising, the winners will be the firms that treat revenue cycle integrity as a core investment thesis, not a compliance checkbox.
For the operators and advisors reading this, the takeaway is just as direct. If you are bringing a healthcare business to market, lead with the metrics that prove cash flow sustainability. Show the buyer that AR days are stable or improving, that payer concentration is manageable, and that the revenue cycle is not a ticking time bomb. That transparency will do more for valuation than any adjusted-EBITDA addback ever will. The market is moving toward a clearer lens, and the firms that adapt will be the ones still standing when the next cycle turns.